iNNO Clinical is changing its name to Aperio Clinical Outcomes. The company says the change is in order to better reflect the company’s dedication to delivering comprehensive clinical research services with unmatched transparency. 

Aperio Clinical Outcomes provides both comprehensive and customizable clinical research services across multiple therapeutic areas. In addition, Aperio offers consulting services in quality assurance, strategic resourcing, and practical application of the latest technologies being implemented in clinical trials.

Faye Woolf, founder and chief executive officer of Aperio, said,  “At Aperio, we’ll tell you plainly what we’re going to do: build the right team, establish strong relationships with sites and clients, and devote ourselves to honest interaction every step of the way. And then we’ll do it, always keeping the human element at the forefront. That’s how we deliver the results our clients deserve.”

The name Aperio comes from the Latin word for “uncover” or “reveal.” That focus on transparency in clinical trials begins with being clear upfront about what projects are a fit for Aperio’s capabilities, and extends through every step in the clinical trial process. 

“We’ll tell you the truth—no matter what,” says Woolf. “We won’t hide uncomfortable facts. We won’t use smoke and mirrors to distort reality. If Aperio can’t do an excellent job for you, we won’t take the work.”